Third Dose of the BNT162b2 Vaccine Results in Sustained High Levels of Neutralizing Antibodies Against SARS-CoV-2 at 6 Months Following Vaccination in Healthy Individuals

• Ioannis Ntanasis-Stathopoulos,
• Vangelis Karalis,
• Aimilia D. Sklirou,
• Maria Gavriatopoulou,
• Harry Alexopoulos,
• Panagiotis Malandrakis,
• Ioannis P. Trougakos,
• Meletios A. Dimopoulos,
• Evangelos Terpos

Affiliations

Ioannis Ntanasis-Stathopoulos

1 Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Greece

Vangelis Karalis

2 Section of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Greece

Aimilia D. Sklirou

3 Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens, Greece

Maria Gavriatopoulou

1 Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Greece

Harry Alexopoulos

3 Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens, Greece

Panagiotis Malandrakis

1 Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Greece

Ioannis P. Trougakos

3 Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens, Greece

Meletios A. Dimopoulos

1 Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Greece

Evangelos Terpos

1 Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Greece